Tomorrow's AALAS annual meeting program includes a session on "Swine Cancer Models: Ready for Prime Time in the Fight to Cure Cancer." Moderated by one of our advisors Raimon Duran-Struuck D.V.M. Ph.D. DACLAM, FAST and featuring advisor Matthew Niemeyer and our VP R&D Kyle Schachtschneider, this session will share the latest on how the Oncopig Cancer Model is transforming preclinical research in oncology. Thanks to these talented researchers for their work to accelerate life-saving cancer therapeutics.
Sus Clinicals, Inc.’s Post
More Relevant Posts
-
🇳🇴 Norway's precision medicine revolution is taking the fight to cancer! Discover how biotech companies like Nykode Therapeutics are teaming up with global pharma to develop innovative cancer vaccines and therapies. The IMPRESS-Norway clinical trial is paving the way for improved public cancer care through precision medicine. Want to know more about Norway's thriving ecosystem and its impact on cancer treatment? Click to learn more👇 #PrecisionMedicine #CancerResearch #BiotechInnovation #NorwegianHealthcare #InvestInNorway
To view or add a comment, sign in
-
We're thrilled to share that Vanessa B. Wookey, MD, an Assistant Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has received a grant from the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) to explore optimizing biomarker-directed therapy in metastatic colorectal cancer. Read more on Wookey’s research program, “Improving Biomarker Testing in Patients With Metastatic Colorectal Cancer Through Patient Education”: https://bit.ly/3qv34L0
Fox Chase Researcher Receives Grant to Explore Biomarker-Directed Therapy in Metastatic Colorectal Cancer
To view or add a comment, sign in
-
Facilitating Partnerships within Biopharma | Crafting CGT and Biologics Manufacturing Conferences Across Europe
🔬 F-Star and Takeda: Forging Next-Gen Cancer Therapies 🌟 Discover the powerful collaboration between F-Star and Takeda that's paving the way for cutting-edge cancer treatments! Dive into the innovation, research, and vision that are driving the future of oncology. 💪 Explore the partnership's impact in our latest article: https://hubs.la/Q022GvKk0
F-star and Takeda Collaborate to Pave the Way for Next-Generation Cancer Therapies
To view or add a comment, sign in
-
NEW from #ASCO2024 | The ABCs of ADCs: what does the future hold? 🎥 🇺🇸 Erika Hamilton, MD, Sarah Cannon Research Institute, delves into the future of #antibodydrugconjugates (#ADCs) in #oncology, encompasses insights from various #disease types, including #myeloma, #lungcancer, and #breastcancer 🩸 🫁 🌟 Dr Hamilton highlights the evolution of #ADCs over the past two decades, emphasizing their expansion beyond highly expressing targets to include #antigens with lower expression levels 🌟 She discusses the promising development of ADCs targeting novel antigens, such as TROP-2, and explores innovative strategies like payload masking and #bispecific targeting to overcome resistance and enhance tolerability 🌟 Dr Hamilton envisions #ADCs revolutionizing #oncologycare and underscores the importance of understanding #antigenexpression and optimizing drug #sequencing in future #research and #clinicalpractice 🔦 Learn more 👉 https://lnkd.in/e2ZN-b8r #VJOncology #Oncologynews American Society of Clinical Oncology (ASCO)
We are thrilled to share the latest advancements in cancer research from our experts at Sarah Cannon Research Institute, presented at the 2024 Annual ASCO Meeting. Erika Hamilton, MD's insights into the future of antibody-drug conjugates (ADCs) highlight exciting new possibilities in oncology. Discover more about these therapies here: https://lnkd.in/e2ZN-b8r Video Journal of Oncology (VJOncology) #CancerExpert #OncologyResearch #ASCO24
The ABCs of ADCs: what does the future hold? - VJOncology
https://www.vjoncology.com
To view or add a comment, sign in
-
A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - Neeraj Agarwal, MD, FASCO Rana McKay Alicia Morgans OncoAlert UroToday + GU OncToday Prostate Cancer Foundation #Cancer #OncoDaily #Oncology #ProstateCancer
Neeraj Agarwal: A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Building on its successful strategy in MM, Johnson & Johnson is tackling solid tumors with a similar approach of combining therapeutic mechanisms. The pharma to present trio of studies on bispecific Rybrevant in lung cancer at #ESMO23
J&J takes on Tagrisso in lung cancer,
biocentury.com
To view or add a comment, sign in
-
🇺🇸🔬 #ASCO2024 | A few takeaways from the American Society of Clinical Oncology (ASCO) Annual Meeting on lung cancer, breast cancer, hepatocellular carcinoma, and melanoma. This confirms high unmet needs where XENOTHERA’s XON7 could bring strong benefits. 👉 For more information on XON7, please refer to our latest press release « XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France » : https://lnkd.in/eFxHhU6V #CancerResearch #Treatment #Oncology #Biotech #Immunotherapy
To view or add a comment, sign in
-
The Cancer Research Institute and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the IPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers. “There is a large body of clinical evidence for LOQTORZI, including positive phase 3 studies published in top-tier scientific journals, showing efficacy and safety in multiple tumor types,” says Jay Campbell, Managing Director, Clinical Accelerator and Venture Fund at CRI. “This level of scientific evidence is what we are looking for when selecting immunotherapies to bring into our network, with the goal of advancing clinically meaningful solutions to patients. We are grateful to have the opportunity to collaborate with Coherus BioSciences and ENB Therapeutics on this study and excited to be working with them on this novel combination that we hope will lead to improved outcomes in these patient populations.” More: https://bit.ly/3QzMzH8 #OvarianCancer #CancerResearch
We are thrilled to have toripalimab selected by Cancer Research Institute (CRI)'s Drug Selection Committee as the PD-1 backbone for exploration in combination with ENB Therapeutics ETBR inhibitor for drug-resistant cancers in an IPROC platform study. We look forward to working with CRI and ENB to potentially advance new therapies for cancer patients.
To view or add a comment, sign in
-
-
A comprehensive review of PARPi+ARPI combos in 1st line mCRPC
A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - Neeraj Agarwal, MD, FASCO Rana McKay Alicia Morgans OncoAlert UroToday + GU OncToday Prostate Cancer Foundation #Cancer #OncoDaily #Oncology #ProstateCancer
Neeraj Agarwal: A comprehensive review of PARPi+ARPI combos in 1st line mCRPC - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
We’re proud to have wonderful partners, like Alex Spira, MD, PhD, FACP, to continue to evaluate the potential of our investigational cMET-targeting ADC for patients with non-small cell lung cancer. Together, we are re-envisioning cancer therapy. Visit our website, below, or contact our team at [email protected] for more information on our trial: https://lnkd.in/ejAiVB_s #KisMET01 #ADC #CancerResearch #Biotechnology #Oncology #NSCLC #LungCancer #ClinicalTrial #LCAM #LungCancerAwareness #LungCancerAwarenessMonth
Clinical Program - Mythic Therapeutics
https://mythictx.com
To view or add a comment, sign in
Partner @ Digitalis Ventures | Board Member, Life Sciences Commercialization
10moSus Clinicals advancing translational preclinical oncology with the Schook Oncopig Cancer Model.